The development of drugs that suppress the expression of Trib3 through the transcriptional regulation or activation of PKC, which specifically regulates COP1 activity, could be a potential strategy to prevent and treat diet- and aging-associated obesity and type 2 diabetes. The gene discussed is TRIB3; the disease is obesity due to melanocortin 4 receptor deficiency.